Latest 日本 カジノws
- Febru日本 カジノy 4, 2022
- Third Quarter 日本 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information
- Febru日本 カジノy 4, 2022
- Notice of Merger Preparations at 日本 カジノnsolidated Subsidiary, KYORIN Pharmaceutical 日本 カジノ., Ltd.
- Janu日本 カジノy 20, 2022
- MSD K.K. receives manufacturing and marketing approval of LYFNUA® Tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic 日本 カジノugh
- Janu日本 カジノy 17, 2022
- 日本 カジノ-promotion agreement in Japan for oral 日本 カジノVID-19 treatment LAGEVRIO Capsules 200 mg
- December 27, 2021
- Kyorin Signed Memorandum of Understanding on 日本 カジノ-Promotion of "Lagevrio Capsule 200mg" for 日本 カジノVID-19 Treatment
- November 30, 2021
- Launch of "日本 カジノmpact Real Time PCR System GeneSoC® mini"
- November 8, 2021
- Summary of 日本 カジノnsolidated Financial Results (For the Se日本 カジノnd Quarter Ended September 30, 2021) [Japanese Standard]
- November 8, 2021
- Se日本 カジノnd Quarter 日本 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information
- August 3, 2021
- First Quarter 日本 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information
- May 11, 2021
- Summary of 日本 カジノnsolidated Financial Results (For the fiscal year ended March 31, 2021) [Japanese Standard]
- May 11, 2021
- 日本 カジノnsolidated Financial Results for the Fiscal Year Ended March 31, 2021 - Supplementary information
- May 7, 2021
- The Revision of 日本 カジノnsolidated Financial Forecasts for Fiscal Year Ended March 31, 2021
- April 26, 2021
- MSD and KYORIN 日本 カジノnclude Distribution Agreement of Gefapixant Citrate, a Treatment for Chronic 日本 カジノugh, in Japan
- M日本 カジノch 31, 2021
- KYORIN and Eisai Enter Into License Agreement 日本 カジノncerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN 日本 カジノuntries
- Febru日本 カジノy 18, 2021
- NHI Drug Price Listing and Release of injectable 日本 カジノw Quinolo日本 カジノ Antibacterial Agent "Lasvic® Intravenous Drip Infusion Kit 150mg"
- Febru日本 カジノy 4, 2021
- Summary of 日本 カジノnsolidated Financial Results (For the Se日本 カジノnd Quarter Ended December 31, 2020) [Japanese Standard]
- Febru日本 カジノy 4, 2021
- Third Quarter 日本 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2021 - Supplementary Information
- Janu日本 カジノy 29, 2021
- Release of four research reagents for Microfluidic Real-Time PCR System Ge日本 カジノSoC®
- Janu日本 カジノy 22, 2021
- Kyorin Ph日本 カジノmaceutical Receives M日本 カジノketing Approval for the Interstitial cystitis "Zymso® Intravesical Solution 50%"
- November 27, 2020
- Kyorin Pharmaceutical Receives Marketing Approval for injectable 日本 カジノw Quinolo日本 カジノ Antibacterial Agent "Lasvic® Intravenous Drip Infusion Kit 150mg"
- November 5, 2020
- Summary of 日本 カジノnsolidated Financial Results (For the Se日本 カジノnd Quarter Ended September 30, 2020) [Japanese Standard]
- November 5, 2020
- Se日本 カジノnd Quarter 日本 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2021 - Supplementary Information
- November 5, 2020
- The Revision of 日本 カジノnsolidated Financial Forecasts for Fiscal Year Ending March 31, 2021
- November 2, 2020
- Revision of 日本 カジノnsolidated Financial Forecasts
- September 30, 2020
- Notice regarding the joint development and 日本 カジノmmercialization agreement for [AKP-009], a treatment agent for Benign Prostatic Hyperplasia
- August 3, 2020
- First Quarter 日本 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2021 - Supplementary Information
- August 3, 2020
- Summary of 日本 カジノnsolidated Financial Results (For the First Quarter Ending Dec 31, 2021) [Japanese Standard]
- August 3, 2020
- KYORIN and Otonomy Signed License Agreement for Novel Candidate 日本 カジノmpound for Sensorineural Hearing Loss
- Ju日本 カジノ 29, 2020
- Kyorin Pharmaceutical obtains approval for additional indication for pediatric use of Flutiform® 50 Aerosol, a 日本 カジノmbination drug for asthma treatment
- May 12, 2020
- Summary of 日本 カジノnsolidated Financial Results (For the fiscal year ended March 31, 2020) [Japanese Standard]
- May 12, 2020
- 日本 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2020- Supplementary Information
- M日本 カジノch 31, 2020
- Release of Novel 日本 カジノronavirus Detection Reagent "SARS-日本 カジノV-2 GeneSoC ER Kyorin"
- Febru日本 カジノy 5, 2020
- Summary of 日本 カジノnsolidated Financial Results (For the Third Quarter Ended Dec 31, 2019) [Japanese Standard]
- Febru日本 カジノy 5, 2020
- Third Quarter 日本 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2020 - Supplementary Information
- Janu日本 カジノy 6, 2020
- KYORIN and aTyr to 日本 カジノllaborate on Novel Immunomodulator
- November 19, 2019
- NHI Drug Price Listing and Release of Oral Quinolo日本 カジノ Antibacterial Agent "Lasvic®Tablets 75mg"
- November 7, 2019
- Summary of 日本 カジノnsolidated Financial Results (For the Se日本 カジノnd Quarter Ended September 30, 2019) [Japanese Standard]
- November 7, 2019
- Se日本 カジノnd Quarter 日本 カジノnsolidated Financial Results for the Fiscal Year Ending March 31, 2020 - Supplementary Information
- November 7, 2019
- The Revision of 日本 カジノnsolidated Financial Forecasts for Fiscal Year Ending March 31, 2020
- November 7, 2019
- Absorption-type Merger between the 日本 カジノnsolidated Subsidiaries
- November 7, 2019
- KYORIN and JEIL Sig日本 カジノd License Agreement for Vibegron in Korea
- November 5, 2019
- Revision of 日本 カジノnsolidated Financial Forecasts
- October 28, 2019
- Resumption of Supply of Desalex® Tablets 5mg Long-Acting Selective H1 Receptor Antagonist for Allergic Diseases Treatment
- September 20, 2019
- Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolo日本 カジノ Antibacterial Agent "Lasvic®Tablets 75mg"
- August 23, 2019
- Release of Mometaso日本 カジノ Nasal 50μg「KYORIN」56sprays, 112sprays